The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > BUSINESS
BUSINESS
- Glivec Receives Add’l Indication for HES/CEL: Novartis Pharma
February 22, 2012
- Cellectis of France Surrenders Claim for Damages Against Shionogi
February 22, 2012
- DSP Obtains Approval for Myslee Generic, Boosting Efforts to Strengthen CNS Field
February 21, 2012
- Pfizer Japan, DSP Apply for Pediatric Indication for Norvasc and Amlodin Based on Data from Public Domain
February 21, 2012
- Astellas, SKK Announce Alliance in Field of Kidney Diseases
February 21, 2012
- Nichi-Iko Makes Yakuhan Subsidiary to Expand Disinfectant Lineup
February 21, 2012
- Kowa Launches Livalo in Mexico through Eli Lilly
February 21, 2012
- Sales of DPP-4 Inhibitors Reach ¥100 Billion Level, Antidiabetic Drugs Show Double-Digit Growth: IMS Japan
February 20, 2012
- Pfizer Japan Ranked No. 1 as Promotion Company: IMS Japan
February 20, 2012
- Qol President Nakamura Says “Proactive Cooperation” Needed for Distribution Improvement
February 20, 2012
- Fuso Acquires Exclusive Domestic Marketing Rights to Mucus Bulging Agent
February 20, 2012
- Daiichi Sankyo, Roche Announce Approval of Malignant Melanoma Treatment Vemurafenib in EU
February 20, 2012
- Diabetes Treatments: Their Development and Market
February 20, 2012
- With Upcoming Price Cuts, Nursing Homes Present Opportunity for Makers of Generic AD Treatments
February 20, 2012
- 6 SGLT-2 Inhibitors in Final Development Stage, Applications Expected in 2013
February 17, 2012
- Qol Expects to Clear “30%” Generic Dispensing Mark Around October
February 17, 2012
- 40% of Doctors Prescribe Existing Drugs Until New Drug Information Is Clarified: Survey
February 17, 2012
- Daiichi Sankyo, Pfizer Obtain Approval for Their Competition Generics for June Listing
February 17, 2012
- Drugstore Chains to Appeal Directly to Public in Support of “Dispensing Point” Services
February 17, 2012
- EC Approves Add’l Indication of CHF for Ion Channel Inhibitor Ivabradine: Ono
February 17, 2012
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…